Erratum: The role of antipsychotics in the management of fibromyalgia (CNS Drugs (2012) 26:2 (135-153) DOI: 10.2165/11597130-000000000-00000);The role of antipsychotics in the management of fibromyalgia

CNS Drugs

Volumn 26, Issue 2, 2012, Pages 135-153

  Calandre, Elena P ^a   Rico Villademoros, Fernando ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Adrenergic uptake inhibitors; Antipsychotics; Fibromyalgia; Gabapentin; Norepinephrine reuptake inhibitors; Pregabalin; Serotonin uptake inhibitors; Tricyclic antidepressants

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; CYCLOBENZAPRINE; DOLASETRON MESILATE; DULOXETINE; FLUPHENAZINE; GABAPENTIN; HALOPERIDOL; LEVOMEPROMAZINE; MILNACIPRAN; NEUROLEPTIC AGENT; OLANZAPINE; OXYBATE SODIUM; PALIPERIDONE; PHENOTHIAZINE; PREGABALIN; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRAZODONE; TRIFLUOPERAZINE; TROPISETRON; UNINDEXED DRUG; ZIPRASIDONE;

ACUPUNCTURE; ANALGESIC ACTIVITY; ANXIETY; ANXIETY DISORDER; ASSAULT; CHIROPRACTIC; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ENVIRONMENTAL FACTOR; EXERCISE; FATIGUE; FIBROMYALGIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HOMEOPATHY; HUMAN; HYDROTHERAPY; HYPERHIDROSIS; HYPERTENSION; INFECTION; MASSAGE; NARCOLEPSY; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REM SLEEP; REVIEW; SEXUAL ABUSE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYMPTOMATOLOGY; WEIGHT GAIN; XEROSTOMIA;

EID: 84856463894     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0066-x     Document Type: Erratum

References (141)

1. Inanci F, Yunus MB. History of fibromyalgia: past to present. Curr Pain Headache Rep 2004 Oct; 8 (5): 369-78 (Pubitemid 39345306)
2. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum 1990; 33: 160-72 (Pubitemid 20098653)
3. World Health Organization. FAQ on ICD: is fibromyalgia included in the International Classification of Diseases [online]? Available from URL: http://www.who.int/classifications/help/icdfaq/en/index.html [Accessed 2011 Jul 4]
4. Wolfe F. New American College of Rheumatology criteria for fibromyalgia: a twenty-year journey. Arthritis Care Res 2010 May; 62 (5): 583-4
5. Nielsen LA, Henriksson KG. Pathophysiological mechanisms in chronic musculoskeletal pain (fibromyalgia): the role of central and peripheral sensitization. Best Pract Clin Res Rheumatol 2007 Jun; 21 (3): 465-80 (Pubitemid 46972010)
6. Arnold LM, Clauw DJ, McCarberg DH, et al. Improving the recognition and diagnosis of fibromyalgia. Mayo Clin Proc 2011 May; 86 (5): 457-64
7. Wolfe F, Claw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010 May; 62 (5): 600-10
8. Moldofsky H. The significance, assessment, and management of nonrestorative sleep in fibromyalgia syndrome. CNS Spectrums 2008 Mar; 13 (3 Suppl. 5): 22-6 (Pubitemid 351532440)
9. Moldofsky H, Lue FA. The relationship of alpha and delta EEG frequencies to pain and mood in 'fibrositis' patients treated with chlorpromazine and L-tryptophan. Electroencephalogr Clin Neurophysiol 1980 Oct; 50 (1-2): 71-80 (Pubitemid 11230079)
10. Branco JC, Martin A, Paiva C. Treatment of sleep abnormalities and clinical complaints in fibromyalgia with trazodone [abstract]. Arthritis Rheum 1996; 39: S91
11. Morillas-Arques P, Rodriguez-Lopez CM,Molina-Barea R, et al. Trazodone for the treatment of fibromyalgia: an open-label, 12-week study. BMC Musculoskelet Disord 2010 Sept 10; 11: 24
12. Moldofsky H, Inhaber NH, Guinta DR, et al. Effects of sodium oxybate on sleep physiology and sleep/wakerelated symptoms in patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. J Rheumatol 2010 Oct; 37 (10): 2156-66
13. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005 Feb; 28 (2): 187-93 (Pubitemid 40362644)
14. Guymer EK, Clauw DJ. Treatment of fatigue in fibromyalgia. Rheum Clin Dis North Am 2002 May; 28 (2): 367-78 (Pubitemid 34733190)
15. Finan PH, Zautra AJ. Fibromyalgia and fatigue: central processing, widespread dysfunction. PM R 2010 May; 2 (5): 431-7
16. Häuser W, Klose P, Langhorst J, et al. Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther 2010; 12 (3): R79
17. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995 Jan; 38 (1): 19-28
18. Farooqi A, Gibson T. Prevalence of the major rheumatic disorders in the adult population of North Pakistan. Br J Rheumatol 1998 May; 37 (5): 491-5
19. White KP, Speechley M, Harth M, et al. The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 1999 Jul; 26 (7): 1570-6 (Pubitemid 29317882)
20. Senna ER, De Barros AL, Silva EO, et al. Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J Rheumatol 2004Mar; 31 (3): 594-7 (Pubitemid 38337624)
21. Haq SA, Darmawan J, Islam MN, et al. Prevalence of rheumatic diseases and associated outcomes in rural and urban communities in Bangladesh: a COPCORD study. J Rheumatol 2005 Feb; 32 (2): 348-53 (Pubitemid 40209136)
22. Branco JC, Bannwarth B, Failde I, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2010 Jun; 39 (6): 448-53
23. Davatchi F, Jamshidi AR, Banihashemi AT, et al. WHOILAR COPCORD Study (Stage 1, Urban Study) in Iran. J Rheumatol 2008 Jul; 35 (7): 1384-90 (Pubitemid 352000789)
24. Reyes-Llerena GA, Guibert-ToledanoM, Penedo-Coello A, et al. Community-based study to estimate prevalence and burden of illness of rheumatic diseases in Cuba: a COPCORD study. J Clin Rheumatol 2009 Mar; 15 (2): 51-5
25. Alvarez-Nemegyei J, Peláez-Ballestas I, Sanin LH, et al. Prevalence of musculoskeletal pain and rheumatic diseases in the southeastern region of Mexico: a COPCORD-based community survey. J Rheumatol Suppl 2011 Jan; 86: 21-5
26. Zeng QY, Zang CH, Lin L, et al. Epidemiologic study of soft tissue rheumatism in Shantou and Taiyuan, China. Chin Med J 2010 Aug 5; 123 (15): 2058-62
27. Bradley LA. Pathophysiology of fibromyalgia. Am J Med 2002 Dec; 122 (12 Suppl.): S22-30
28. Di Franco M, Iannucelli C, Valesini G. Neuroendocrine immunology of fibromyalgia. Ann N Y Acad Sci 2010 Apr; 1193: 84-90
29. Staud R. Autonomic dysfunction in fibromyalgia syndrome: postural orthostatic tachycardia. Curr Rheumatol Rep 2008 Dec; 10 (6): 463-6
30. Wood PB, Holman AJ. An elephant among us: the role of dopamine in the pathophysiology of fibromyalgia. J Rheumatol 2009 Feb; 36 (2): 221-4
31. Al-Allaf AW, Dunbar KL, Hallum NS, et al. A casecontrol study examining the role of physical trauma in the onset of fibromyalgia syndrome. Rheumatology 2002 Apr; 41 (4): 450-3 (Pubitemid 34537845)
32. Buskila D, Atzeni F, Sarzi-Puttini P. Etiology of fibromyalgia: the possible role of infection and vaccination. Autoimmunity Rev 2008 Oct; 8 (1): 41-3
33. Häuser W, Kosseva M, Üceyler N, et al. Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta-analysis. Arthritis Care Res 2011 Jun; 63 (6): 808-20
34. Van Houdenhove B, Egle UT. Fibromyalgia: a stress disorder? Piecing the biopsychosocial puzzle together. Psychother Psychosom 2004 Sep-Oct; 73 (5): 267-75 (Pubitemid 39060995)
35. Lyon P, Cohen M, Quintner J. An evolutionary stressresponse hypothesis for chronic widespread pain (fibromyalgia syndrome). Pain Med 2011 Aug; 12 (8): 1167-78
36. Martinez-Lavin M. Biology and therapy of fibromyalgia: stress, the stress response system, and fibromyalgia. Arthritis Res Ther 2007; 9 (4): 216
37. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum 2008 Jun; 37 (6): 339-52
38. Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology to therapy. Nat Rev Rheumatol 2011 Jul 19; 7 (9): 518-27
39. Wolfe F, Michaud K, Li T, et al. Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erytemathosus, and fibromyalgia. J Rheumatol 2010 Feb; 37 (2): 305-15
40. Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol 2006 Jun; 12 (3): 124-8 (Pubitemid 44314970)
41. Bennett RM, Jones J, Turk DC, et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 2007 Mar 9; 8: 27
42. Bennett RM, Friend R, Jones KD, et al. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther 2009; 11 (4): R120
43. Häuser W, Schmutzer G, Bráhler E, et al. A cluster within the continuum of biopsychosocial distress can be labeled 'fibromyalgia syndrome': evidence from a representative German population survey. J Rheumatol 2009 Dec; 36 (12): 2806-12
44. Wolfe F, Michaud K. Outcome and predictor relationships in fibromyalgia and rheumatoid arthritis: evidence concerning the continuum versus discrete disorder hypothesis. J Rheumatol 2009 Apr; 36 (4): 831-6
45. Smith HS, Barkin RL. Fibromyalgia syndrome: a discussion of the syndrome and pharmacotherapy. Dis Month 2011 May; 57 (5): 248-85
46. Hassett AL, Gevirtz RN. Nonpharmacologic treatment for fibromyalgia: patient education, cognitive-behavioral therapy, relaxation techniques, and complementary and alternative medicine. Rheum Dis Clin North Am 2009 May; 35 (2): 393-407
47. Bennett R, Nelson D. Cognitive behavioral therapy for fibromyalgia. Nat Clin Pract Rheumatol 2006 Aug; 2 (8): 416-24 (Pubitemid 44203825)
48. van Koulil S, Effting M, Kraaimaat FW, et al. Cognitivebehavioural therapies and exercise programmes for patients with fibromyalgia: state of the art and future directions. Ann Rheum Dis 2007 May; 66 (5): 571-81 (Pubitemid 46707124)
49. Thieme K, Gracely RH. Are psychological treatments effective for fibromyalgia pain? Curr Rheumatol Rep 2009 Dec; 11 (6): 443-50
50. Glombiewski JA, Sawyer AT, Gutermann J, et al. Psychological treatments for fibromyalgia: a meta-analysis. Pain 2010 Nov; 151 (2): 280-95
51. Langhorst J, Klose P, Musial F, et al. Efficacy of acupuncture in fibromyalgia syndrome: a systematic review with a meta-analysis of controlled clinical trials. Rheumatology (Oxford) 2010 Apr; 49 (4): 778-88
52. Terry R, Perry R, Ernst E. An overview of systematic reviews of complementary and alternative medicine for fibromyalgia. Clin Rheumatol. Epub 2011 May 26
53. De Silva V, El-Metwally A, Ernst E, et al. Evidence for the efficacy of complementary and alternative medicines in the management of fibromyalgia: a systematic review. Rheumatology (Oxford) 2010 Jun; 49 (6): 1063-8
54. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008 Apr; 67 (4): 536-41 (Pubitemid 351498437)
55. Häuser W, Bernardy K, Üçeyler N, et al. Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials. Pain 2009 Sep; 145 (1-2): 69-81
56. Bockbrader HN, Wesche D, Miller R, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010 Oct; 49 (10): 661-9
57. Verdu B, Decosterd I, Buclin T, et al. Antidepressants for the treatment of chronic pain. Drugs 2008; 68 (18): 2611-32
58. Häuser W, Bernardy K, Üçeyler N, et al. Treatment of fibromyalgia syndrome with antidepressants: a metaanalysis. JAMA 2009 Jan; 301 (2): 198-209
59. Häuser W, Petzke F,Üçeyler N, et al. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology 2011 Mar; 50 (3): 532-43
60. Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum 2004 Feb; 51 (1): 9-13 (Pubitemid 38222276)
61. Choy EH, Mease PJ, Kajdasz DK, et al. Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials. Clin Rheumatol 2009 Sep; 28 (9): 1035-44
62. Chwieduk CM, McCormack PL. Milnacipran in fibromyalgia. Drugs 2010; 70 (1): 99-108
63. Chappell AS, Littlejohn G, Kajdasz DK, et al. A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clin J Pain 2009 Jun; 25 (5): 365-75
64. Branco JC, Cherin P, Montagne A, et al. Longterm therapeutic response to milnacipran treatment for fibromyalgia: a European 1-year extension study following a 3-month study. J Rheumatol 2011 Jul; 38 (7): 1403-12
65. Spath M, Stratz T, Farber L, et al. Treatment of fibromyalgia with tropisetron: dose and efficacy correlations. Scand J Rheumatol Suppl 2004; 119: 63-6 (Pubitemid 39180192)
66. Vergne-Salle P, Dufauret-Lombard C, Bonnet C, et al. A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia. Eur J Pain 2011 May; 15 (5): 509-14
67. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005 Aug; 52 (8): 2495-505 (Pubitemid 41117437)
68. Russell IJ, Kamin M, Bennett RM, et al. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 2000 Oct; 6 (5): 250-7
69. Bennett RM, Kamin M, Karim R, et al. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebocontrolled study. Am J Med 2003 May; 114 (7): 537-45 (Pubitemid 36577256)
70. Russell IJ, Holman AJ, Swick TJ, et al. Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: results from a 14-week, randomized, double-blind, placebo-controlled study. Pain 2011 May; 152 (5): 1007-17
71. Staud R. Sodium oxybate for the treatment of fibromyalgia. Expert Opin Pharmacother 2011 Aug; 12 (11): 1789-98
72. Felson DT, Goldenberg DL. The natural history of fibromyalgia. Arthritis Rheum 1986 Dec; 29 (12): 1522-6 (Pubitemid 17003893)
73. Wolfe F, Anderson J, Harkness D, et al. Health status and disease severity in fibromyalgia: results of a six-center longitudinal study. Arthritis Rheum 1997 Sep; 40 (9): 1571-9 (Pubitemid 27426149)
74. Baumgartner E, Finckh A, Cedraschi C, et al. A six year prospective study of a cohort of patients with fibromyalgia. Ann Rheum Dis 2002 Jul; 61 (7): 644-5 (Pubitemid 34717780)
75. Noller V, Sprott H. Prospective epidemiological observations on the course of the disease in fibromyalgia patients. J Negat Results Biomed 2003 Aug 23; 2: 4
76. St John AB, Born CK. Characterization of analgesic and activity effects of methotrimeprazine and morphine. Res Commun Chem Pathol Pharmacol 1979 Oct; 26 (1): 25-34 (Pubitemid 10191313)
77. Gleeson RM, Atrens DM. Chlorpromazine hyperalgesia antagonizes clonidine analgesia but enhances morphine analgesia in rats tested in a hot-water tail-flick paradigm. Pyschopharmacology 1982; 78 (2): 141-6 (Pubitemid 13234092)
78. Golbidi S, Moriuchi H, Irie T, et al. Involvement of calmodulin inhibition in analgesia induced with low doses of intrathecal trifluoperazine. Jpn J Pharmacol 2002 Feb; 88 (2): 151-7 (Pubitemid 34223564)
79. Ghelardini C, Galeotti N, Uslenghi C, et al. Prochlorperazine induces central antinociception mediated by the muscarinic system. Pharmacol Res 2004 Sep; 50 (3): 351-8 (Pubitemid 38844491)
80. Dong XW, Jia Y, Lu SX, et al. The antipsychotic drug, fluphenazine, effectively reverses mechanical allodynia in rat models of neuropathic pain. Psychopharmacology (Berl) 2007 Jan; 195 (4): 559-68
81. Chen YW, Chu CC, Chu KS, et al. Phenotiazine-type antipsychotics elicit cutaneous analgesia in rats. Acta Anaesthesiol Taiwan 2010 Mar; 48 (1): 3-7
82. Head M, Lal H, Puri S, et al. Enhancement of morphine analgesia after acute and chronic haloperidol. Life Sci 1979 May 28; 24 (22): 2037-44 (Pubitemid 10229687)
83. Cendan CM, Pujalte JM, Portillo-Salido E, et al. Antinociceptive effects of haloperidol and its metabolites in the formalin test in mice. Psychopharmacology (Berl) 2005 Nov; 182 (4): 485-93 (Pubitemid 41464629)
84. Entrena JM, Cobos EJ, Nieto FR, et al. Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors. Psychopharmacology 2009 Jul; 205 (1): 21-33
85. Schreiber S, Backer MM, Weizman R, et al. Augmentation of opioid-induced antinociception by the atypical antipsychotic drug risperidone in mice. Neurosci Lett 1997 May 30; 228 (1): 25-8 (Pubitemid 27288528)
86. DiPirro JM, Thompson AC, Suarez M, et al. Low doses of risperidone and morphine interact to produce more analgesia and greater extrapyramidal effects in rats. Neurosci Lett 2011 Feb 18; 490 (1): 21-6
87. Schreiber S, Getslev V, Backer MM, et al. The atypical neuroleptics clozapine and olanzapine differ regarding their antinociceptive mechanisms and potency. Pharmacol Biochem Behav 1999 Sep; 64 (1): 75-80 (Pubitemid 29415798)
88. Weizman T, Pick CG, Backer MM, et al. The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol 2003 Oct 8; 478 (2-3): 155-9 (Pubitemid 37315734)
89. Kowalski J, Huzarska M, Jasinski R. Effect of fluphenazine on the footshock-induced opioid analgesia and leu-enkephalin concentration in the rat brain. Pol J Pharmacol Pharm 1988 Nov-Dec; 40 (6): 621-5 (Pubitemid 19208536)
90. Patt RB, Proper G, Reddy S. The neuroleptics as adjuvant analgesics. J Pain SymptomManage 1994 Oct; 9 (7): 446-53 (Pubitemid 24338146)
91. Robertson CE, Black DF, Swanson JW. Management of migraine headache in the emergency department. Semin Neurol 2010 Apr; 30 (2): 201-11
92. Pridmore S, Samilowitz H, Oberoi G. Will the atypical antipsychotics be analgesic? Australas Psychiatry 2003 March; 11 (1): 59-61
93. Fishbain DA, Cutler RB, Lewis J, et al. Do the second generation 'atypical neuroleptics' have analgesic properties? A structured evidence-based review. Pain Med 2004 Dec; 5 (4): 359-65 (Pubitemid 40103620)
94. Seidel S, Aigner M, Ossege M, et al. Antipsychotics for acute and chronic pain in adults. Cochrane Database Syst Rev 2008 Oct 8; (4): CD004844
95. Seidel S, Aigner M, Ossege M, et al. Antipsychotics for acute and chronic pain in adults. J Pain Symptom Manage 2010 Apr; 39 (4): 678-778
96. Maina G, Vitalucci A, Gandolfo S, et al. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. J Clin Psychiatry 2002 Jan; 63 (1): 38-43 (Pubitemid 34113485)
97. Bogetto F, Bonatto-Revello R, Ferro G, et al. Trattamento psicofarmacologico della burning mouth syndrome (BMS): studio su di un campioni de 121 pazienti. Minerva Psichiatrica 1999; 40 (1): 1-10 (Pubitemid 29174169)
98. Clavel M, Pommatau E. Analgesic effects of tiapride in man: a double-blind comparative clinical trial against placebo (author's transl). Sem Hop 1980 Mar; 56 (9-10): 430-3 (Pubitemid 10097291)
99. Krymchantowski AV, Jevoux C, Moreira PF. An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine. Pain Med 2010 Jan; 11 (1): 48-52
100. Arnold LM, Crofford LJ, Martin SA, et al. The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med 2007 Nov-Dec; 8 (8): 633-8 (Pubitemid 350142910)
101. Jensen KB, Petzke F, Carville S, et al. Anxiety and depressive symptoms in fibromyalgia are related to poor perception of health but not to pain sensitivity or cerebral processing pain. Arthritis Rheum 2010 Nov; 62 (11): 3488-95
102. Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997 Sep; 40 (9): 1560-70 (Pubitemid 27426148)
103. Gao K, Gajwani P, Elhaj O, et al. Typical and atypical antipsychotics in bipolar depression. J Clin Psychiatry 2005 Nov; 66 (11): 1376-85 (Pubitemid 41779535)
104. Gao K, Muzina D, Gajwani P, et al. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry 2006 Sept; 67 (9): 1327-40 (Pubitemid 44583379)
105. Vulink NCC, Figee M, Denys D. Review of atypical antipsychotics in anxiety. Eur Neuropsychopharmacol 2011 Jun; 21 (6): 429-49
106. Lalonde CD, Van Lieshout RJ. Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and metaanalysis. J Clin Psychopharmacol 2011 Jun; 31 (3): 326-33
107. Pies R. Should psychiatrists use atypical antipsychotics to treat nonpsychotic anxiety? Psychiatry 2009 Jun; 6 (6): 29-37
108. Kukopulos A, Reginaldi D, Laddomada P, et al. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol 1980 Jul; 13 (4): 156-67 (Pubitemid 10048336)
109. Harrow M, Yonan CA, Sands JR, et al. Depression in schizophrenia: are neuroleptics, akinesia or anhedonia involved? Schizophrenia Bull 1994; 20 (2): 327-38 (Pubitemid 24171095)
110. DeBattista C, Hawkins J. Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs 2009; 23 (5): 369-77
111. Cruz N, Sanchez-Moreno J, Torres F, et al. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol 2010 Feb; 13 (1): 5-14
112. Brugue E, Vieta E. Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Progr Neuropsychopharmacol Biol Psychiatry 2007 Jan 30; 31 (1): 275-82 (Pubitemid 44959242)
113. Komossa K, Depping AM, Gaudchaud A, et al. Secondgeneration antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010 Dec 8; (12): CD008121
114. Cohrs S. Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics. CNS Drugs 2008; 22 (11): 939-62
115. Promethazine: prescribing information [online]. Available from URL: http://www.rxlist.com/phenergan-drug.htm [Accessed 2011 May 15]
116. Nozinan-: product monograph [online]. Available from URL: http://www.sanofi-aventis.ca/products/en/nozinan. pdf [Accessed 2011 May 21]
117. Aukst-Margeti B, Margeti B, Tosi G, et al. Levomepromazine helps to reduce sleep problems in patients with PTSD. Eur Psychiatry 2004 Jun; 19 (4): 235-6
118. Sharpley AL, Vassallo CM, Cowen PJ. Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT2C receptors in vivo. Biol Psychiatry 2000 Mar 1; 47 (5): 468-70 (Pubitemid 30110618)
119. Sharpley AL, Vassallo CM, Pooley EC, et al. Allelic variation in the 5-HT2C receptor (HT2RC) and the increase in slow wave sleep produced by olanzapine. Psychopharmacology (Berl) 2001 Jan 1; 153 (2): 271-2 (Pubitemid 32127899)
120. Lindberg N, Virkkunen M, Tani P, et al. Effect of a single-dose of olanzapine on sleep of healthy females and males. Int Clin Psychopharmacol 2002 Jul; 17 (4): 177-84 (Pubitemid 34686788)
121. Gimenez S, Clos S, Romero S, et al. Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers. Psychopharmacoloy (Berl) 2007 Mar; 190 (4): 507-16 (Pubitemid 46204468)
122. Cohrs S, Rodenbeck A, Guan Z, et al. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl) 2004 Jul; 174 (3): 421-9 (Pubitemid 39044301)
123. Cohrs S, Meier A, Neumann AC, et al. Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: a randomized, controlled, crossover trial of 12 healthy male subjects. J Clin Psychiatry 2005 Aug; 66 (8): 989-96 (Pubitemid 41191790)
124. Patat A, Rosenzweig P, Miget N, et al. Effects of 50 mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep deprived subjects. Fundam Clin Pharmacol 1999; 13 (5): 582-94
125. Kiser RS, Cohen HM, Freedenfeld RN, et al. Olanzapine for the treatment of fibromyalgia symptoms. J Pain Symptom Manage. 2001 Aug; 22 (2): 704-8 (Pubitemid 32725813)
126. Shemo M, Shemo JPD, Anderson M. Beneficial effects of quetiapine treatment in patients with fibromyalgia [abstract]. J Neuropsychiatry Clin Neurosci Spring 2003; 15 (2): 282
127. Rico-Villademoros F, Hidalgo J, Dominguez I, et al. Atypical antipsychotics in the treatment of fibromyalgia: a case series with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2005 Jan; 29 (1): 161-4 (Pubitemid 40021786)
128. Freedenfeld RN, Murray M, Fuchs PN, et al. Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic. Pain Pract 2006 Jun; 6 (2): 112-8 (Pubitemid 43676681)
129. Hidalgo J, Rico-Villademoros F, Calandre EP. An openlabel study of quetiapine in the treatment of fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry 2007 Jan; 31 (1): 71-7 (Pubitemid 44959248)
130. Calandre EP, Hidalgo J, Rico-Villademoros F. Use of ziprasidone in patients with fibromyalgia: a case series. Rheumatol Int 2007 Mar; 27 (5): 473-6 (Pubitemid 46294988)
131. Rico-Villademoros F, Hidalgo J, Morillas-Arques P, et al. An open-label study of levopromazine (methotrimeprazine) as an add-on therapy in fibromyalgia management. Clin Exp Rheumatol 2009 Sep-Oct; 27 (5 Suppl. 56): S16-20
132. McIntyre A. A study of quetiapine fumarate sustained release in major depression with comorbid fibromyalgia syndrome [ClinicalTrials.gov identifier NCT00675896]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 July 20]
133. Moore NC. Quetiapine compared with placebo in the management of fibromyalgia [ClinicalTrials.gov identifier NCT00710918]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 July 20]
134. Calandre EP. Comparative efficacy and tolerability of quetiapine XR and amitriptyline in the treatment of fibromyalgia [ClinicalTrials.gov identifier NCT00766350]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 July 20]
135. Marchand S. Quetiapine (Seroquel XR) for the treatment of fibromyalgia: a clinical and mechanistic pilot study [ClinicalTrials.gov identifier NCT00983320]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 July 20]
136. Pardini M, Guida S, Primavera A, et al. Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. Eur Neuropsychopharmacol 2011 Mar; 21 (3): 282-6
137. Moore N, Macmillan P, Birur B, et al. Fibromyalgia: efficacy of quetiapine compared with placebo [abstract no. NR08-48:333]. 164th Annual Meeting of the American Psychiatric Association; 2011 May 14-18; Honolulu (HI)
138. Rico-Villademoros F, Rodríguez Löpez CM, V́lchez Perez JS, et al. Comparison between quetiapine-XR and amitriptyline in fibromyalgia patients: a 16-week, randomized, open-label, non-inferiority trial [abstract]. Eur J Pain 2011 Sep; 5 (1): 133
139. Gao K, Ganocy SJ, Gajwani P, et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 2008 Feb; 69 (2): 302-9 (Pubitemid 351469274)
140. Wang Z, Kemp DE, Chan PK, et al. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder. Int J Neuropsychopharmacol 2011 Feb; 14 (1): 131-42
141. Calandre EP, Morillas-Arques P, Rodriguez-Lopez CM, et al. Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia. Pharmacopsychiatry 2007 Mar; 40 (2): 68-71 (Pubitemid 46697677)